Endurant Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Endurant Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-119,979	Closed	-$276K	–	80
2020 Q2	$276K	Sell	119,979 -144,328	-55%	-$332K	0.02%	54
2020 Q1	$455K	Buy	264,307 +26,100	+11%	+$52.7K	0.21%	47
2019 Q4	$493K	Buy	238,207 +50,079	+27%	+$119K	0.16%	47
2019 Q3	$546K	Sell	188,128 -101,586	-35%	-$347K	0.2%	46
2019 Q2	$1.14M	Buy	+289,714	New	+$1.51M	0.45%	43

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Endurant Capital Management's GNCA Position: Q3 2020 in Review

Endurant Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2020, closing a stake of 119,979 shares — an estimated $276K sold.

Endurant Capital Management first reported a position in GNCA in Q2 2019 and held it in 5 quarters. The position peaked at $1.14M in Q2 2019. 39 funds tracked by Wall St. Rank hold GNCA as of Q3 2020.

Endurant Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q3 2020 after selling out during the quarter.
Endurant Capital Management sold 119,979 Genocea Biosciences, Inc. shares in Q3 2020, an estimated $276K.
Endurant Capital Management first reported a position in Genocea Biosciences, Inc. in Q2 2019 and held it in 5 quarters.
Endurant Capital Management's Genocea Biosciences, Inc. position peaked at $1.14M in Q2 2019.
39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2020.

Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.